Treprostinil palmitil | CAS#1706528-83-7 | prodrug of treprostinil

Treprostinil palmitil
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 130292

CAS#: 1706528-83-7

Description: Treprostinil palmitil is the prodrug of treprostinil (TRE), having an extended duration of activity with reduced side effects as compared to TRE. The powdered version of Treprostinil palmitil, which is inhaled, has been found to increase anti-inflammatory and antifibrotic activity in rodents modelling asthma and pulmonary fibrosis. The powdered form is undergoing clinical trials.

Chemical Structure

Treprostinil palmitil

CAS# 1706528-83-7

Instruction

Theoretical Analysis

MedKoo Cat#: 130292
Name: Treprostinil palmitil
CAS#: 1706528-83-7
Chemical Formula: C39H66O5
Exact Mass: 614.49
Molecular Weight: 614.950
Elemental Analysis: C, 76.17; H, 10.82; O, 13.01

Price and Availability

Size	Price	Availability
5mg	USD 515	2 Weeks
10mg	USD 900	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Treprostinil palmitil; INS1009; INS 1009; INS-1009

IUPAC/Chemical Name: hexadecyl 2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetate

InChi Key: XOKCXRVJBBLBSX-HDMCCQRMSA-N

InChi Code: InChI=1S/C39H66O5/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-19-26-43-39(42)30-44-38-23-20-21-31-27-35-32(28-36(31)38)29-37(41)34(35)25-24-33(40)22-18-6-4-2/h20-21,23,32-35,37,40-41H,3-19,22,24-30H2,1-2H3/t32-,33-,34+,35-,37+/m0/s1

SMILES Code: O=C(OCCCCCCCCCCCCCCCC)COC1=C2C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@H](O)C3)([H])CC2=CC=C1

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 614.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1. : Chapman RW, Li Z, Chun D, Gauani H, Malinin V, Plaunt AJ, Cipolla D, Perkins WR, Corboz MR. Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats. Pulm Pharmacol Ther. 2021 Feb;66:101983. doi: 10.1016/j.pupt.2020.101983. Epub 2020 Dec 17. PMID: 33346142.

2: Corboz MR, Plaunt AJ, Malinin V, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. Eur J Pharmacol. 2022 Feb 5;916:174484. doi: 10.1016/j.ejphar.2021.174484. Epub 2021 Sep 9. PMID: 34508752.

3: Chapman RW, Corboz MR, Fernandez C, Sullivan E, Stautberg A, Plaunt AJ, Konicek DM, Malinin V, Li Z, Cipolla D, Perkins W. Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. ERJ Open Res. 2021 Feb 15;7(1):00592-2020. doi: 10.1183/23120541.00592-2020. PMID: 33614774; PMCID: PMC7882781.

4: Corboz MR, Plaunt AJ, Malinin VS, Li Z, Gauani H, Chun D, Cipolla D, Perkins WR, Chapman RW. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. J Pharmacol Exp Ther. 2022 Oct;383(1):103-116. doi: 10.1124/jpet.122.001174. Epub 2022 Aug 31. PMID: 36507843.

5: Plaunt AJ, Islam S, Macaluso T, Gauani H, Baker T, Chun D, Viramontes V, Chang C, Corboz MR, Chapman RW, Li Z, Cipolla DC, Perkins WR, Malinin VS. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. Int J Mol Sci. 2021 Jan 7;22(2):548. doi: 10.3390/ijms22020548. PMID: 33430435; PMCID: PMC7828008.

6: Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. Adv Ther. 2022 Nov;39(11):5144-5157. doi: 10.1007/s12325-022-02296-x. Epub 2022 Sep 7. PMID: 36070132; PMCID: PMC9525339.

7: Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, Li Z, Perkins WR. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020 Dec;65:102002. doi: 10.1016/j.pupt.2021.102002. Epub 2021 Feb 15. PMID: 33596473.

8: Croasdell G. European Society of Cardiology (ESC) Congress 2021 (August 27-30, 2021 - Virtual Meeting). Drugs Today (Barc). 2021 Oct;57(10):639-643. doi: 10.1358/dot.2021.57.10.3365971. PMID: 34713872.

Your view history

Treprostinil palmitil featured